K
Keyur P. Patel
Researcher at University of Texas MD Anderson Cancer Center
Publications - 319
Citations - 10772
Keyur P. Patel is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 42, co-authored 319 publications receiving 7448 citations. Previous affiliations of Keyur P. Patel include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials
Funda Meric-Bernstam,Lauren Brusco,Kenna R. Mills Shaw,Chacha Horombe,Scott Kopetz,Michael A. Davies,Mark J. Routbort,Sarina Anne Piha-Paul,Filip Janku,Naoto T. Ueno,David S. Hong,John de Groot,Vinod Ravi,Yisheng Li,Raja Luthra,Keyur P. Patel,Russell Broaddus,John Mendelsohn,Gordon B. Mills +18 more
TL;DR: Broad implementation of multiplex hotspot testing is feasible; however, only a small portion of patients with actionable alterations were actually enrolled onto genotype-matched trials, and the challenges for trial enrollment are reported.
Journal ArticleDOI
Ibrutinib and venetoclax for first-line treatment of CLL
Nitin Jain,Michael J. Keating,Philip A. Thompson,Alessandra Ferrajoli,Jan A. Burger,Gautam Borthakur,Koichi Takahashi,Zeev Estrov,Nathan Fowler,Tapan M. Kadia,Marina Konopleva,Yesid Alvarado,Musa Yilmaz,Courtney D. DiNardo,Prithviraj Bose,Maro Ohanian,Naveen Pemmaraju,Elias J. Jabbour,Koji Sasaki,Rashmi Kanagal-Shamanna,Keyur P. Patel,Jeffrey L. Jorgensen,Naveen Garg,Xuemei Wang,Katrina Sondermann,Nichole Cruz,Chongjuan Wei,Ana Ayala,William Plunkett,Hagop M. Kantarjian,Varsha Gandhi,William G. Wierda +31 more
TL;DR: Combined venetoclax and ibrutinib was an effective oral regimen for high-risk and older patients with CLL and the proportions of patients who had complete remission or complete remission with incomplete count recovery and remission with undetectable minimal residual disease increased over time.
Journal ArticleDOI
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.
Courtney D. DiNardo,Ing Soo Tiong,Ing Soo Tiong,A. Quaglieri,Sarah MacRaild,Sanam Loghavi,Fiona C. Brown,Rachel Thijssen,Giovanna Pomilio,Adam Ivey,Jessica M. Salmon,Christina Glytsou,Shaun Fleming,Shaun Fleming,Qi Zhang,Huaxian Ma,Keyur P. Patel,Steve Kornblau,Zhen Xu,Chong Chyn Chua,Chong Chyn Chua,Xufeng Chen,Piers Blombery,Piers Blombery,Piers Blombery,Christoffer Flensburg,Nik Cummings,Ioannis Aifantis,Hagop M. Kantarjian,David C.S. Huang,Andrew W. Roberts,Andrew W. Roberts,Ian J. Majewski,Marina Konopleva,Andrew H. Wei,Andrew H. Wei +35 more
TL;DR: Molecular determinants of outcome with clinical relevance to patients with AML receiving venetoclax-based combination therapies are identified, highlighting the dynamic and rapid occurrence of therapeutic selection in AML.
Journal ArticleDOI
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.
Naval Daver,Guillermo Garcia-Manero,Sreyashi Basu,Prajwal Boddu,Mansour Alfayez,Jorge E. Cortes,Marina Konopleva,Farhad Ravandi-Kashani,Elias Jabbour,Tapan M. Kadia,Graciela M. Nogueras-Gonzalez,Jing Ning,Naveen Pemmaraju,Courtney D. DiNardo,Michael Andreeff,Sherry Pierce,Tauna Gordon,Steven M. Kornblau,Wilmer Flores,Zainab Al-Hamal,Carlos E. Bueso-Ramos,Jeffrey L. Jorgensen,Keyur P. Patel,Jorge Blando,James P. Allison,Padmanee Sharma,Hagop M. Kantarjian +26 more
TL;DR: Azacitidine in combination with nivolumab therapy produced an encouraging response rate and overall survival in patients with R/R AML, particularly in HMA-naïve and salvage 1 patients.
Journal ArticleDOI
Clinical Validation of a Next-Generation Sequencing Screen for Mutational Hotspots in 46 Cancer-Related Genes
Rajesh R. Singh,Keyur P. Patel,Mark J. Routbort,Neelima Reddy,Bedia A. Barkoh,Brian Handal,Rashmi Kanagal-Shamanna,Wesley O. Greaves,L. Jeffrey Medeiros,Kenneth D. Aldape,Rajyalakshmi Luthra +10 more
TL;DR: The IT-PGM platform with the ability to multiplex and simultaneously sequence multiple patient samples using low amounts of FFPE DNA was specific and sensitive for single nucleotide variant mutation analysis and can be incorporated easily into the clinical laboratory for routine testing.